Advertisement
CARD vs LABD
Which ETF would AI Choose? Max Auto Industry -3X Inverse Leveraged ETN (CARD) vs. Direxion Daily S&P Biotech Bear 3X ETF (LABD)
Key Takeaways
- CARD provides -3x daily inverse exposure to a liquidity-weighted index of U.S. auto industry companies, while LABD delivers -3x daily inverse exposure to an equal-weighted index of U.S. biotechnology stocks.
- Both ETFs use leveraged inverse structures with synthetic exposure via swaps and derivatives rather than direct stock holdings, resulting in high volatility and suitability primarily for short-term trading.
- CARD carries a 0.95% expense ratio and is structured as an exchange-traded note (ETN) issued by Bank of Montreal, whereas LABD has a 1.07% expense ratio and operates as an open-ended ETF from Direxion.
- CARD targets the consumer discretionary automotive sector with exposure to manufacturers, parts suppliers, and dealers; LABD focuses exclusively on the healthcare biotechnology sub-industry.
- Structural differences include CARD’s ETN format (credit risk from issuer) versus LABD’s ETF structure, alongside varying rebalancing mechanics inherent to daily leveraged products.
- Relative positioning depends on sector-specific momentum in autos versus biotech, with both products amplifying daily moves in their respective underlying indexes.
Introduction
Investors seeking leveraged inverse exposure often compare products across distinct sectors to align with specific market views. CARD and LABD do not compete directly for the same thematic exposure; instead, they offer alternative strategies for bearish positioning—one in the automotive industry and the other in biotechnology. This comparison highlights structural distinctions, sector allocations, and positioning within current market cycles to assist investors evaluating short-term tactical opportunities.
Max Auto Industry -3X Inverse Leveraged ETN (CARD) Overview
CARD seeks daily investment results, before fees and expenses, of 300% of the inverse of the daily performance of the Prime Auto Industry Index. The index tracks U.S.-listed companies involved in automobile manufacturing, parts, retail, and car dealing, using a modified liquidity-weighted methodology. As a leveraged inverse ETN, CARD employs synthetic exposure through derivatives and maintains no direct equity holdings. It features an expense ratio of 0.95% and was launched in June 2023. Distinguishing features include its ETN structure, which introduces issuer credit risk, and its narrow focus on the North American auto supply chain excluding certain foreign issuers.
Direxion Daily S&P Biotech Bear 3X ETF (LABD) Overview
LABD seeks daily investment results, before fees and expenses, of 300% of the inverse of the daily performance of the S&P Biotechnology Select Industry Index. This equal-weighted index measures the biotechnology sub-industry based on the Global Industry Classification Standard (GICS). LABD utilizes swaps, futures, and other derivatives for synthetic inverse exposure and operates as an open-ended ETF with a 1.07% expense ratio. Launched in 2015, it distributes dividends periodically. Key characteristics include its non-diversified nature, focus solely on U.S. biotech firms, and daily reset mechanism typical of leveraged products.
Industry and Thematic Backdrop
The automotive sector faces ongoing transitions toward electric vehicles, supply chain adjustments, and sensitivity to consumer spending and interest rates. The biotechnology industry contends with clinical trial outcomes, regulatory approvals, funding environments, and broader healthcare policy shifts. Macroeconomic factors such as interest rate expectations and capital allocation between growth-oriented sectors influence both areas. Regulatory developments in emissions standards or drug pricing can act as catalysts, while sector risks include technological disruption in autos and binary event-driven volatility in biotech.
Performance and Positioning Comparison
In recent market cycles, both ETFs have exhibited amplified daily movements consistent with their -3x mandates, with performance diverging based on relative strength or weakness in autos versus biotech. CARD’s positioning benefits from auto industry rotations tied to manufacturing data and consumer demand trends, while LABD responds to biotech earnings cycles and innovation pipelines. Volatility differences arise from the underlying indexes’ characteristics, with LABD often reflecting higher event risk from clinical developments. Relative positioning favors tactical use aligned with sector momentum rather than long-term holding.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore opportunities with the AI Screener today.
Tickeron AI Verdict
Based on structural strength, cost efficiency, diversification profile, trend consistency, sector momentum, and risk exposure, Tickeron’s AI would currently assign a modest probabilistic edge to LABD. Its longer operating history, ETF structure without issuer credit considerations, and established liquidity profile in the biotech space provide observable advantages in a daily-reset leveraged framework, though both products remain suited exclusively for short-term tactical applications.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CARD is a Hold and LABD is a Hold.
Momentum Indicator for CARD turns negative, indicating new downward trend
CARD saw its Momentum Indicator move below the 0 level on October 26, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 59 similar instances where the indicator turned negative. In 57 of the 59 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for CARD turned negative on October 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 34 similar instances when the indicator turned negative. In 31 of the 34 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
CARD moved below its 50-day moving average on October 29, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CARD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for CARD's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +2.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where CARD advanced for three days, in 155 of 174 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
CARD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 85 of 95 cases where CARD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.
Momentum Indicator for LABD turns negative, indicating new downward trend
LABD saw its Momentum Indicator move below the 0 level on October 26, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned negative. In 86 of the 89 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for LABD turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 49 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LABD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
LABD broke above its upper Bollinger Band on October 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 59 of 61 cases where LABD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
LABD moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for LABD crossed bullishly above the 50-day moving average on October 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +11.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where LABD advanced for three days, in 248 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 155 of 160 cases where LABD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
| CARD | LABD | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 81% | N/A |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Advances ODDS (%) | 16 days ago 89% | 2 days ago 90% |
| Declines ODDS (%) | 2 days ago 90% | 6 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 89% | 2 days ago 90% |
Advertisement